Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
87 hedge funds and large institutions have $623M invested in Avadel Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 40 increasing their positions, 15 reducing their positions, and 15 closing their positions.
216% more call options, than puts
Call options by funds: $3.88M | Put options by funds: $1.23M
167% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 15
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
18% more capital invested
Capital invested by funds: $527M → $623M (+$96M)
4% more funds holding
Funds holding: 84 → 87 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$16.1M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$10.8M |
| 3 |
Bank of New York Mellon
New York
|
+$9.93M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.13M |
| 5 |
CPIM
Columbia Partners Investment Management
Alexandria,
Virginia
|
+$7.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$32.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.3M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$15.7M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$10.7M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$6.9M |
AVDL Hedge Fund Activity: Q2 2015 in Review
87 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2015, worth a combined $623M — up 18% from $527M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AVDL positions and 15 closed out — a net gain of 3 holders — while 40 added to existing stakes and 15 trimmed.
The largest buyer was Portolan Capital Management, opening a new position worth an estimated $16.1M. The largest seller was Millennium Management, cutting an estimated $32.2M.
- 87 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2015, up from 84 in Q1 2015.
- Funds reported $623M of Avadel Pharmaceuticals stock for Q2 2015, up 18% quarter-over-quarter.
- 18 funds opened new Avadel Pharmaceuticals positions in Q2 2015 and 15 closed out, a net change of +3 holders.
- The largest Avadel Pharmaceuticals buyer in Q2 2015 was Portolan Capital Management, an estimated $16.1M added.
- The largest Avadel Pharmaceuticals seller in Q2 2015 was Millennium Management, an estimated $32.2M sold.
Based on aggregated 13F filings for Q2 2015.